Lipopharma designs and develops potentially transformative synthetic bio-active lipids that specifically interact with key signal-transduction peripheral proteins involved in the pathogeny of serious diseases like cancer, CNS, inflammatory or metabolic diseases.




Lipopharma aims to develop next-generation medicines based on the novel MLT strategy, which targets membrane lipid-signal transduction protein interactions.




Innovative MLT-based drugs will soon become reference treatments worldwide for serious diseases with important medical needs unmet, such as glioblastoma and other aggressive cancer malignancies, as well as neuro-degenerative, metabolic, cardiovascular or inflammatory diseases, providing a safe and efficacious therapeutic alternative that will bring dramatic improvements in the clinical outcome and in the quality of life for an important number of patients with these pathologies

Supported by



© 2019 Lipopharma | legal notice Copyright 2011 Lipopharma - Company. All Rights Reserved.
Joomla 1.7 templates by hostgator coupon and learn how to make a website